Reports Q3 revenue $69.228M, consensus $74.85M. “During the third quarter, we achieved important milestones, including the successful launch of VYVGART in China for patients with generalized myasthenia gravis and the positive pivotal trial readout for efgartigimod in chronic inflammatory demyelinating polyneuropathy,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “These developments underscore our unwavering commitment to delivering innovative medicines to patients in need. With new drug applications under review by the National Medical Products Administration and multiple ongoing pivotal trials evaluating drugs with significant market potential, we are well-positioned to accelerate our pipeline and to expand our portfolio of commercial assets as we work to elevate patient care worldwide.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZLAB:
- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab price target lowered to $64 from $67 at JPMorgan
- Cantor biotech/biopharma analysts to hold an analyst/industry conference call
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
Questions or Comments about the article? Write to editor@tipranks.com